Noninvasive evaluation of nonalcoholic fatty liver disease

Clinical Liver Disease

Volumn 7, Issue 3, 2016, Pages 45-47

  Renelus, Benjamin ^a   Foster, Temitope ^b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b Dekalb Gastroenterology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 6;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; ECHOGRAPHY; ELASTOGRAPHY; FIBROSIS 4 SCORE; HEPATIC STEATOSIS INDEX; HUMAN; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MORBID OBESITY; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; NONALCOHOLIC FATTY LIVER DISEASE LIVER FAT SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; STEATOTEST;

EID: 84961885050     PISSN: None     EISSN: 20462484     Source Type: Journal    
DOI: 10.1002/cld.538     Document Type: Review

References (13)

1. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-1219.
3. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014;60:1920-1928.
4. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208-1216.
5. Noureddin M, Loomba R. Nonalcoholic fatty liver disease: indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis 2012;1:104-107.
6. Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol 2013;28(suppl 4):64-70.
7. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-675.
8. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014;20:7718-7729.
9. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013;1:7.
10. Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, et al. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int 2012;32:629-634.
11. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009;50:1072-1078.
12. Shen J, Chan HL, Wong GL, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012;56:1363-1370.
13. Patel K, Wilder J. Fibroscan. Clin Liver Dis 2014;4:97-101.